Navigation Links
PharmAthene Reports Year-End 2007 Financial Results
Date:3/31/2008

able - 11,768,089

Current portion of long term debt 4,000,000 -

Total current liabilities 8,996,550 14,194,226

Warrants to purchase Series C convertible

redeemable preferred stock - 2,423,370

Other long-term liabilities 374,040 -

Long term debt 16,668,458 -

Total liabilities 26,039,048 16,617,596

Minority interest -- Series C convertible

redeemable preferred stock of PharmAthene

Canada, Inc. $0.001 par value; unlimited

shares authorized; 2,591,654 issued and

outstanding; liquidation preference in the

aggregate of $2,719,178 - 2,545,785

Series A convertible redeemable preferred

stock; $0.001 par value; 16,442,000 shares

authorized, issued and outstanding; liquidation

preference in the aggregate of $19,355,388 - 19,130,915

Series B convertible redeemable preferred

stock; $0.001 par value; 65,768,001 shares

authorized; 30,448,147 issued and outstanding;

liquidation preference in the aggregate of

$33,010,797 - 31,780,064

Series C convertible redeemable preferred

stock; $0.001 par value; 22,799,574 shares

authorized; 14,946,479 issued and outstanding;

liquidation preference in the aggregate of

$15,681,930 - 14,480,946

Stockholders' deficit:

Common stock, $0.0001 par value;

100,000,000 shares authorized; 22,138,723

and 22,087,121 shares issued and

outstanding; respectively at December 31,

2007 and 621,281 shares issued and

outstanding at Decembe
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... 30, 2014 Grace Century portfolio project, ... Manganello, Chairman of the Board, to the National Stem ... appointment was made by the Ministry of Health on behalf ... , More than a year after Bahamian Parliament ... Prime Minister Perry Christie said the government has completed the ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... , October 27, 2014 ... right to produce, exhibit and sell its artificial ... to impeach their patent.      (Photo: ... four years of fighting, the definitive judgement has ... and produces innovative and accessible hi-tech prostheses with ...
Breaking Biology Technology:Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... NeuroCog Trials, Inc. today announced the appointment of Michael ... Officer.  In this newly created position, Dr. Hufford will ... NeuroCog Trials, business, research and development, and operations. ... therapies across a wide variety of therapeutic areas has ...
... November 4, 2011 Major milestone achieved ... treatment of patients with refractory ascites due to liver ... Vienna and Vienna General Hospital (AKH Wien) reported that ... System were performed at Vienna General Hospital in October, ...
... Nov. 3, 2011 Sequenom, Inc. (NASDAQ: SQNM ), ... total revenues of $13.6 million for the third quarter of 2011, ... the third quarter of 2010.  Net loss for the third quarter ... to net loss of $22.7 million, or $0.30 per share for ...
Cached Biology Technology:NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer 2The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump® System 2Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 2Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 3Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 4Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 5Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 6Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 7Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 8
(Date:10/30/2014)... University researchers have developed a suite of technologies that ... humans, which has applications in everything from search and ... "We,ve developed a platform for computer-mediated communication between humans ... for interpreting dogs, behavioral signals and sending them clear ... an assistant professor of computer science at NC State ...
(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
(Date:10/29/2014)... factors, both genetic and environmental, have been blamed ... schizophrenia. Some, such as a family history of ... with Toxoplasma gondii , a parasite transmitted ... still viewed with skepticism. , A new study ... epidemiology at the University of Pennsylvania,s School of ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... have found that a strain of tuberculosis (TB) responsible ... first introduced to these communities by French Canadian fur ... found a traceable link between the fur trade routes ... professor with Queen,s Division of Infectious Diseases, is the ...
... Melding nanotechnology and medical research, Sandia National Laboratories, the ... and Treatment Center have produced an effective strategy that ... of killer drugs. , In the cover article of ... online April 17 , the researchers describe silica nanoparticles ...
... Monday, April 18, 2011, Cleveland: Researchers have identified ... as the cause of a fatal developmental disease in ... April 8, 2011, issue of Science . ... the cellular protein-making process, causing microcephalic osteodysplastic primoridal dwarfism ...
Cached Biology News:Tuberculosis strain in indigenous communities linked to Canadian fur trade 2Sandia and UNM lead effort to destroy cancers 2Sandia and UNM lead effort to destroy cancers 3Genetic mutation linked to lethal disease 2
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
... (Ankyrin repeat and SOCS box-containing protein) This ... containing amino acids 75-93 and 348-368 of ... Catalog No. 40149) can be used as ... with mouse and rat Asb-2, based on ...
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Biology Products: